Cover Image
市場調查報告書

Raptor Pharmaceuticals Corp.- 產品平台分析

Raptor Pharmaceuticals Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 203737
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Raptor Pharmaceuticals Corp.- 產品平台分析 Raptor Pharmaceuticals Corp. - Product Pipeline Review - 2015
出版日期: 2015年11月30日 內容資訊: 英文 34 Pages
簡介

Raptor Pharmaceuticals Corp. (Raptor)開發著可治療讓人衰弱甚至致命的疾病,可改變患者一生的劃時代治療法,並將之商品化。

本報告提供Raptor Pharmaceuticals Corp.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Raptor Pharmaceuticals Corp.的基本資料

Raptor Pharmaceuticals Corp.概要

  • 主要資訊
  • 企業資料

Raptor Pharmaceuticals Corp.:R&D概要

  • 主要的治療範圍

Raptor Pharmaceuticals Corp.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Raptor Pharmaceuticals Corp.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
  • IND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床階段的產品/聯合治療模式
  • ■Raptor Pharmaceuticals Corp.:開發階段不明的開發中產品
  • 開發階段不明的產品/聯合治療模式

Raptor Pharmaceuticals Corp.:藥物簡介

  • cysteamine DR
  • fomepizole
  • Cysteamine Dioxygenase Inhibitor
  • HepTide
  • NGX-426
  • tezampanel

Raptor Pharmaceuticals Corp.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Raptor Pharmaceuticals Corp.:最近的開發平台趨勢

Raptor Pharmaceuticals Corp.:暫停中的計劃

Raptor Pharmaceuticals Corp.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
  • NGX-426
  • tezampanel
  • WntTide

Raptor Pharmaceuticals Corp.:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07822CDB

Summary

Global Markets Direct's, 'Raptor Pharmaceuticals Corp. - Product Pipeline Review - 2015', provides an overview of the Raptor Pharmaceuticals Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Raptor Pharmaceuticals Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Raptor Pharmaceuticals Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Raptor Pharmaceuticals Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Raptor Pharmaceuticals Corp.'s pipeline products

Reasons to buy

  • Evaluate Raptor Pharmaceuticals Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Raptor Pharmaceuticals Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Raptor Pharmaceuticals Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Raptor Pharmaceuticals Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Raptor Pharmaceuticals Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Raptor Pharmaceuticals Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Raptor Pharmaceuticals Corp. Snapshot
    • Raptor Pharmaceuticals Corp. Overview
    • Key Information
    • Key Facts
  • Raptor Pharmaceuticals Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Raptor Pharmaceuticals Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Raptor Pharmaceuticals Corp. - Pipeline Products Glance
    • Raptor Pharmaceuticals Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Raptor Pharmaceuticals Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Raptor Pharmaceuticals Corp. - Drug Profiles
    • cysteamine DR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fomepizole
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HepTide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Cysteamine Dioxygenase for Cystinosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Raptor Pharmaceuticals Corp. - Pipeline Analysis
    • Raptor Pharmaceuticals Corp. - Pipeline Products by Target
    • Raptor Pharmaceuticals Corp. - Pipeline Products by Route of Administration
    • Raptor Pharmaceuticals Corp. - Pipeline Products by Molecule Type
    • Raptor Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action
  • Raptor Pharmaceuticals Corp. - Recent Pipeline Updates
  • Raptor Pharmaceuticals Corp. - Dormant Projects
  • Raptor Pharmaceuticals Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • WntTide
  • Raptor Pharmaceuticals Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Raptor Pharmaceuticals Corp., Key Information
  • Raptor Pharmaceuticals Corp., Key Facts
  • Raptor Pharmaceuticals Corp. - Pipeline by Indication, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Stage of Development, 2015
  • Raptor Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2015
  • Raptor Pharmaceuticals Corp. - Out-Licensed Products in Pipeline, 2015
  • Raptor Pharmaceuticals Corp. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Raptor Pharmaceuticals Corp. - Phase II, 2015
  • Raptor Pharmaceuticals Corp. - Preclinical, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Target, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Route of Administration, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Molecule Type, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action, 2015
  • Raptor Pharmaceuticals Corp. - Recent Pipeline Updates, 2015
  • Raptor Pharmaceuticals Corp. - Dormant Developmental Projects,2015
  • Raptor Pharmaceuticals Corp. - Discontinued Pipeline Products, 2015
  • Raptor Pharmaceuticals Corp., Subsidiaries

List of Figures

  • Raptor Pharmaceuticals Corp. - Pipeline by Top 10 Indication, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Stage of Development, 2015
  • Raptor Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2015
  • Raptor Pharmaceuticals Corp. - Out-Licensed Products in Pipeline, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Top 10 Target, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Raptor Pharmaceuticals Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top